Finnish biopharmaceutical company Desentum closes financial round totalling nearly EUR 2 Million
ESPOO, Finland, Jan. 23, 2017- Today, Desentum, a biopharmaceutical company developing next generation immunotherapy to fight allergies, announced that it has completed a Series A...











